Suppr超能文献

4-氢过氧环磷酰胺诱导的4-氢过氧环磷酰胺敏感和耐药髓母细胞瘤细胞系中c-myc基因DNA链间交联的修复分析

Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.

作者信息

Dong Q, Bullock N, Ali-Osman F, Colvin O M, Bigner D D, Friedman H S

机构信息

Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.

出版信息

Cancer Chemother Pharmacol. 1996;37(3):242-46. doi: 10.1007/BF00688323.

Abstract

Cyclophosphamide is one of the most active agents in the treatment of medulloblastoma. However, development of resistance to this alkylator frequently occurs and is the harbinger of tumor progression and death. In order to understand the biochemical basis of this resistance, we generated a panel of medulloblastoma cell lines in our laboratory that were resistant to 4-hydroperoxycyclophosphamide (4-HC). Previously, we have shown that elevated levels of aldehyde dehydrogenase and glutathione mediate cellular resistance to 4-HC. The present study was conducted to identify the third unknown mechanism mediating the resistance of cell line D283 Med (4-HCR) to 4-HC, testing the hypothesis that this resistance is mediated by an increased repair of DNA interstrand crosslinks (ICLs). The doses of 4-HC that produced a one- and two-log cell kill of D283 Med cells were 25 and 50 microM, respectively, compared with values of 125 and 165 microM in D283 Med (4-HCR), the resistant cell line. The formation and disappearance of 4-HC-induced DNA ICLs at the c-myc gene were subsequently studied by DNA denaturing/renaturing gel electrophoresis and Southern blot analysis. 4-HC-induced DNA ICLs in the c-myc gene exhibited a dose-dependent relationship. The percentage of the c-myc gene that was crosslinked was approximately 1-3% at a dose of 100 microM. More than 50% of the DNA crosslinking in D283 Med (4-HCR) cells was removed by 6 h after drug treatment, whereas, in D283 Med cells, more than 90% of the DNA crosslinking was still present at 6 h. These findings suggest that the increased repair of DNA ICLs in D283 Med (4-HCR) may contribute significantly to its resistance to 4-HC.

摘要

环磷酰胺是治疗髓母细胞瘤最有效的药物之一。然而,对这种烷化剂产生耐药性的情况经常发生,并且是肿瘤进展和死亡的先兆。为了了解这种耐药性的生化基础,我们在实验室中建立了一组对4-氢过氧环磷酰胺(4-HC)耐药的髓母细胞瘤细胞系。此前,我们已经表明,醛脱氢酶和谷胱甘肽水平的升高介导了细胞对4-HC的耐药性。本研究旨在确定介导细胞系D283 Med(4-HCR)对4-HC耐药性的第三种未知机制,检验这种耐药性是由DNA链间交联(ICL)修复增加介导的这一假设。产生D283 Med细胞1个对数和2个对数细胞杀伤的4-HC剂量分别为25和50微摩尔,而耐药细胞系D283 Med(4-HCR)的值为125和165微摩尔。随后通过DNA变性/复性凝胶电泳和Southern印迹分析研究了4-HC诱导的c-myc基因处DNA ICL的形成和消失。4-HC诱导的c-myc基因处DNA ICL呈现剂量依赖性关系。在100微摩尔的剂量下,c-myc基因交联的百分比约为1-3%。药物处理后6小时,D283 Med(4-HCR)细胞中超过50%的DNA交联被去除,而在D283 Med细胞中,6小时时仍有超过90% 的DNA交联存在。这些发现表明,D283 Med(4-HCR)中DNA ICL修复的增加可能对其对4-HC的耐药性有显著贡献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验